Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Cp Cvr (CELGZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.40 +17.50%
on 11/20/19
0.53 -11.32%
on 10/31/19
+0.01 (+2.15%)
since 10/18/19
3-Month
0.40 +17.50%
on 11/20/19
1.24 -62.10%
on 09/26/19
-0.08 (-14.55%)
since 08/20/19
52-Week
0.35 +34.29%
on 12/28/18
1.65 -71.52%
on 03/12/19
-0.40 (-45.98%)
since 11/20/18

Most Recent Stories

More News
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P 500 prior to the open of trading on Thursday,...

CELGZ : 0.45 (-2.17%)
TMO : 307.24 (+0.27%)
CELG : 108.05 (-0.07%)
NOW : 280.73 (+1.08%)
BMY : 55.87 (-1.08%)
SPGI : 269.72 (+0.69%)
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index(R) (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the...

CELGZ : 0.45 (-2.17%)
EXC : 45.21 (-0.35%)
CELG : 108.05 (-0.07%)
NDAQ : 105.46 (+0.37%)
Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the "Exchange...

CELGZ : 0.45 (-2.17%)
BMY : 55.87 (-1.08%)
CELG : 108.05 (-0.07%)
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

--Transaction Expected to Close on November 20, 2019

CELGZ : 0.45 (-2.17%)
BMY : 55.87 (-1.08%)
CELG : 108.05 (-0.07%)
AMGN : 225.63 (+0.50%)
Celgene Receives CHMP Positive Opinion for REVLIMID(R) (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma

--The positive opinion was based on the results of the Phase 3 AUGMENT study, which showed the R(2) regimen conferred a statistically significantly improvement in progression-free survival versus rituximab...

CELGZ : 0.45 (-2.17%)
CELG : 108.05 (-0.07%)
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued...

CELGZ : 0.45 (-2.17%)
BMY : 55.87 (-1.08%)
CELG : 108.05 (-0.07%)
Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET(TM) Immunotherapy Drug Candidate

Dragonfly to receive a $12M in-licensing payment and is eligible to receive potential future milestones and royalties on net sales.

CELGZ : 0.45 (-2.17%)
Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET(TM) Immunotherapy Drug Candidate

Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced it has licensed another TriNKET(TM) immunotherapy drug candidate to Celgene Corporation and its affiliates ("Celgene"). Today's...

CELGZ : 0.45 (-2.17%)
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.

CELGZ : 0.45 (-2.17%)
CELG : 108.05 (-0.07%)
Editas Medicine Announces Third Quarter 2019 Results and Update

Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine

CELGZ : 0.45 (-2.17%)
EDIT : 24.52 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar